MDXG · NASDAQ
MiMedx Group, Inc.
$3.57 -0.33 (-8.46%)
Company overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes human placental tissues using its patented and proprietary PURION process to produce allografts that retain the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft comprising dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord, dehydrated human umbilical cord allografts used to provide a protective environment for the healin…
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $520M
- Employees
- 837
- Headquarters
- Marietta, GA
- Website
- mimedx.com
- CEO
- Joseph H. Capper
- Listed
- February 12, 2008
- P/E
- 17.41
- Dividend yield
- 0.00%
Company financials
- Revenue
- $389M
- Gross profit
- $316M
- Operating income
- $39.6M
- EBITDA
- $55.4M
- Net income
- $30.7M
- EPS
- $0.21
- Total assets
- $309M
- Total debt
- $1.5M
- Gross margin
- 81.04%
- Net margin
- 7.88%
- Earnings yield
- 5.75%
No geographic segmentation.
Showing FY 2025
MDXG
1D
NASDAQ
O3.86H3.90L3.79C3.90+0.05 (+1.30%)Vol1.92M